A Retro-Prospective Observational Study of Ibrutinib Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical Practice
Phase of Trial: Phase IV
Latest Information Update: 22 Nov 2018
At a glance
- Drugs Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia; Mantle-cell lymphoma
- Focus Therapeutic Use
- Acronyms FIRE
- Sponsors Janssen-Cilag
- 08 Nov 2018 Planned number of patients changed from 500 to 600.
- 08 Nov 2018 Planned End Date changed from 22 May 2024 to 22 May 2022.
- 28 Jun 2018 Planned End Date changed from 22 May 2022 to 22 May 2024.